IL-10 delivery by AAV5 vector attenuates inflammation in mice with Pseudomonas pneumonia.

Lung infections with Pseudomonas aeruginosa and other pathogens in cystic fibrosis (CF) cause progressive airway obstruction and tissue damage, the predominant cause of morbidity and mortality in CF. We investigated whether a recombinant adeno-associated virus type 5 (AAV5) vector expressing murine interleukin (IL)-10 (AAV5.Cbeta-mIL-10), a regulatory/anti-inflammatory cytokine, could decrease airway inflammation in IL-10 knockout mice chronically infected with mucoid P. aeruginosa. Mice that received AAV5.Cbeta-mIL10 through intratracheal inoculation produced IL-10 at an average of 25 000 pg/ml in the epithelial lining fluid (ELF) and 12 000 pg/g-lung tissue 6 weeks post-vector delivery, significantly higher levels than in placebo-treated mice. At 3 days post-infection, proinflammatory cytokines (IL-1beta, tumor necrosis factor (TNF)-alpha, macrophage inhibitory protein (MIP)-1alpha and (KC) in the ELF and lung homogenate were decreased (1-9 folds) in the AAV5.Cbeta-mIL10-treated mice accompanied by less pronounced and more localized neutrophil infiltration in lung sections, when compared with placebo-treated mice. These results suggest that AAV5.Cbeta-mIL10 induces IL-10 levels in the lungs mediating a significant anti-inflammatory response and making AAV-IL-10 gene transfer a potentially useful therapy in the treatment of CF lung disease.

Oral instillation with surfactant phospholipid: a reliable alternative to intratracheal injection in mouse studies.

The intratracheal (IT) injection technique has been widely used in the mouse studies of pulmonary diseases. Here, we describe a non-invasive technique using oral instillation challenge with the surfactant phospholipid that may advantageously replace the traditional IT technique. We performed comparative studies between oral instillation and IT injection of both vectors (adeno-associated virus, AAV vector) and bacteria (Pseudomonas aeruginosa). Our results demonstrated that the oral instillation is a reliable alternative to IT injection. The administration of a fluorophore-labelled AAV vector demonstrated a similar pattern of distribution and quantity of vector delivered by oral instillation compared with IT injection. In addition, administration of AAV5-alpha-1 antitrypsin (AAT) to the lungs by oral instillation resulted in similar levels of AAT in both the lung homogenates and sera compared with the IT injection group. In our study of P. aeruginosa delivery, oral instillation resulted in similar mouse weight loss, cytokine levels in the epithelial lining fluid [interleukin (IL)-1beta, IL-6, tumour necrosis factor-alpha, neutrophil chemokine and macrophage inflammatory protein-1alpha], lung histology/pathology and bacterial loads. Therefore, we conclude that oral instillation of materials mixed with surfactant phospholipid is an adequate and reproducible technique to replace the invasive IT injection procedure for the delivery of either vector or bacteria to the lungs. This procedure has the benefits of eliminating the discomfort, local inflammation and mortality associated with the more invasive IT surgical procedures.